Author

J.-F. Peyron

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:benchmarking· 1 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1 Assay:metabolomics· 1

Frequent Co-Authors

A. Kypraios· 1 shared A. Petit· 1 shared A. Sahal· 1 shared B. Gaillard· 1 shared B. Uzan· 1 shared C. Antoniewski· 1 shared C. Bosc· 1 shared C. Recher· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Kypraios

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

High CD44 expression identifies rare chemoresistant leukemic cells endowed with enhanced E-Selectin binding in T-ALL

J. Calvo, I. Naguibneva, A. Kypraios, B. Uzan, B. Gaillard, L. Bellenger, L. Renou, C. Antoniewski, H. Lapillone, A. Petit, P. Ballerini, S. J. Mancini, T. Marchand, J.-F. Peyron, F. Pflumio

The paper identifies a chemoresistant leukemic stem cell population in T-ALL with high CD44 expression and enhanced E-selectin binding, associated with poor prognosis and relapse.

bioRxiv · Dec 20, 2023 · PreprintCancer Biology

FAO-supported OxPhos leukemic stem cells are sensitive to cold.

E. Griessinger, D. Pereira-Martins, M. Nebout, C. Bosc, E. Saland, E. Boet, A. Sahal, J. Chiche, D. Debayle, L. Fleuriot, M. Pruis, V. De Mas, F. Vergez, C. Recher, G. Huls, , J.-F. Peyron

The paper identifies cold sensitivity as a vulnerability in FAO-supported OxPhos leukemic stem cells, which can be exploited for therapeutic targeting.

bioRxiv · Apr 17, 2023 · PreprintCancer Biology